Current or history of congestive heart failure New York Heart Association (NYHA) class  or , or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < %, as measured by MUGA scan or echocardiogram); prior to study entry, any electrocardiography (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
Patients must not have a cardiac ejection fraction < % or the presence of New York Heart Association stage III or IV heart failure within  days prior to registration; either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to determine ejection fraction
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than %; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multigated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)
Current or history of congestive heart failure New York Heart Association (NHYA) class  or , or any history of documented diastolic or systolic dysfunction (LVEF < %, as measured by MUGA scan or echocardiogram)
Have current or a history of congestive heart failure New York Heart Association (NYHA) class  or , or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < %, as measured by multigated acquisition [MUGA] scan or echocardiogram)
Patients must have a left ventricular ejection fraction >= %, no uncontrolled arrhythmias or New York Heart Association class III-IV heart failure
Left ventricular ejection fraction (LVEF) that is greater than %, or the absence of New York Heart Association (NYHA) classification of greater than stage II congestive heart failure
Inadequate cardiac function, as measured by left ventricular ejection fraction (LVEF) that is less than or equal to %, or the presence of New York Heart Association (NYHA) classification of greater than stage II congestive heart failure
New York Heart Association (NYHA) Class III or IV heart failure and/or ejection fraction of < % as measured by echocardiogram at screening.
Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < % by echocardiogram or multi-gated acquisition (MUGA) scan
Cardiac conditions as follows: patient has a history of congestive heart failure (CHF) class III/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment; patient has a cardiac ejection fraction < % by either echocardiogram or multi-gated acquisition (MUGA) scan
Cardiac: Uncontrolled clinically significant arrhythmias; clinical evidence of significant congestive heart failure (CHF) (NYHA Class III or IV); left ventricular ejection fraction (LVEF) < % by echocardiogram
New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, stable or unstable angina, symptoms of coronary artery disease, congestive heart failure, clinically significant hypotension, or history of an ejection fraction of =<  % (echocardiogram or multi gated acquisition scan [MUGA])
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by MUGA scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)
Patients with active unstable angina, concomitant clinically significant active arrhythmias, myocardial infarction within  months, or congestive heart failure New York Heart Association class III-IV; patients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) < % are excluded
History of significant cardiac disease, particularly uncompensated congestive heart failure New York Heart Association (NYHA) grade  or more or left ventricular ejection fraction (LVEF) < % on any prior assessment; (assessment of LVEF prior to therapy is not required in the absence of other clinical indicators of heart disease); patients with a prior LVEF < % will require-evaluation prior to study entry
Congestive heart failure New York Heart Association (NYHA) Class III or IV or history of congestive heart failure NYHA class III or IV, unless an echocardiogram or multigated acquisition scan performed within  months before day  reveals a left ventricular ejection fraction ? %;
Congestive heart failure (New York Heart Association [NYHA] class III/IV) or left ventricular ejection fraction (LVEF) < % at baseline
Patients must not have ejection fraction decrease > % from baseline (as determined by ECHO) or other ejection fraction decrease accompanied by other clinical signs/symptoms of New York Heart Association (NYHA) class III or IV heart failure, measured within  days prior to registration; if any question exists regarding individual patient eligibility in this situation, contact the study chair for determination
Subject has congestive heart failure New York Heart Association (NYHA) class  or , or subject with a history of congestive heart failure NYHA class  or  in the past, unless a screening echocardiogram performed within  months prior to study entry results in a left ventricular ejection fraction that is ? %.
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than %; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately  days of CD.
Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within approximately  days of CD
Current or history of congestive heart failure New York Heart Association (NYHA) class  or , or any history of documented diastolic or systolic dysfunction (LVEF < %, as measured by MUGA scan or echocardiogram)
Patients with history of myocardial infarct within  months before enrollment, New York Heart Association (NYHA) class II or greater heart failure or symptoms suspicious for congestive heart failure are not eligible unless a Left ventricular ejection fraction (LVEF) in the past  months is documented to be % or greater; patients who have had a LVEF (performed for any reason) that is less than % in the past  months are ineligible
Congestive heart failure New York Heart Association (NYHA) Class III or IV or history of congestive heart failure NYHA Class III or IV in the past, unless a Screening echocardiogram or multi-gated acquisition scan performed within  months before the Day  visit reveals a left ventricular ejection fraction that is ? %.
New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, stable or unstable angina, symptoms of coronary artery disease (CAD), congestive heart failure, clinically significant hypotension or history of an ejection fraction of =< % (echocardiogram or multi-gated acquisition scan [MUGA])
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by echocardiogram, or cardiac magnetic resonance imaging (MRI)
Patients must have a left ventricular ejection fraction > %, no uncontrolled arrhythmias or New York Heart Association class III-IV heart failure
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately  days of CD.
Subject has congestive heart failure New York Heart Association (NYHA) class  or , or subject with a history of congestive heart failure NYHA class  or  in the past, unless a screening echocardiogram performed within  months prior to study entry results in a left ventricular ejection fraction that is ? %.
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately  days of CD.
Significant cardiac disease:\r\n* Congestive heart failure > class II New York Heart Association (NYHA)\r\n* Myocardial infarction within  months prior to study entry\r\n* Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin\r\n* Serious myocardial dysfunction, defined as scintigraphically (multi gated acquisition scan [MUGA], myocardial scintigram) or echocardiogram determined absolute left ventricular ejection fraction (LVEF) below normal (< %)
The following groups of patients are eligible provided they have New York Heart Association class II (NYHA) cardiac function on baseline echocardiogram (ECHO)/multi gated acquisition scan (MUGA):\r\n* Those with a history of class II heart failure who are asymptomatic on treatment\r\n* Those with prior anthracycline exposure\r\n* Those who have received central thoracic radiation that included the heart in the radiotherapy port
Patients must not have a history of cardiac disease, defined as New York Heart Association class II or greater or clinical evidence of congestive heart failure; all patients must have a MUGA scan or -dimensional (D) echocardiogram indicating an ejection fraction of >= % within  days prior to registration; the method used at baseline must be used for later monitoring
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction < % by multi-gated acquisition (MUGA) scan or by transthoracic echocardiogram
Major cardiac dysfunction, such as uncontrolled angina, congestive heart failure with New York Heart Association (NYHA) class III or higher, known left ventricular ejection fraction less than %
Patients with any class of New York Heart Association (NYHA) CHF or heart failure with preserved ejection fraction (HFPEF)
History of myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure (New York Heart Failure [NYHA] class III or IV congestive heart failure) within  months prior to study enrollment or left ventricular ejection fraction (LVEF) < %
History of congestive heart failure New York Heart Association (NYHA) class  or  in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within three months results in a left ventricular ejection fraction that is ? %;
New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, stable or unstable angina, symptoms of coronary artery disease, congestive heart failure, clinically significant hypotension, or an ejection fraction of =<  % (echocardiogram or MUGA)
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately  days of CD
Subject has congestive heart failure New York Heart Association (NYHA) class  or , or subject with a history of congestive heart failure NYHA class  or  in the past, unless a screening echocardiogram performed within  months prior to study entry results in a left ventricular ejection fraction that is ? %
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or known ejection fraction < % by multi gated acquisition scan (MUGA) or < % by echocardiogram and/or magnetic resonance imaging (MRI)
Congestive heart failure New York Heart Association (NYHA) class  or , or subjects with history of congestive heart failure NYHA class  or  in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months of the Screening visit results in a left ventricular ejection fraction that is ? %
The following groups of patients are eligible after consultation with a cardiologist and at the coordinating center PIs discretion, provided they have New York Heart Association class II (NYHA) cardiac function on baseline echocardiogram (ECHO)/multigated acquisition scan (MUGA):\r\n* Those with a history of class II heart failure who are asymptomatic on treatment\r\n* Those with prior anthracycline exposure greater than a cumulative dose of  mg/m^\r\n* Those who have received central thoracic radiation that included the heart in the radiotherapy port
Any of the following cardiovascular conditions or values within  months before the first dose of study drug:\r\n* A left-ventricular ejection fraction < %\r\n* Myocardial infarction within  years of randomization\r\n* New York Heart Association (NYHA) class III or IV heart failure
Patients with diagnosed New York Heart Association (NYHA) class III-IV failure or documented ejection fraction (EF) < %
Have current or a history of congestive heart failure New York Heart Association (NYHA) class  or , or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < %, as measured by multigated acquisition [MUGA] scan or echocardiogram)
Congestive heart failure of New York Heart Association Class ?  or known left ventricular ejection fraction < %, or
Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class  or  or subject has a history of congestive heart failure NYHA class  or  in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within  month prior to study entry results in a left ventricular ejection fraction that is ? %.
Normal left ventricular ejection fraction at baseline and no evidence of New York Heart Association class II to IV heart failure
Confirmed left ventricular ejection fraction ?% or any cardiac insufficiency > New York Heart Association (NYHA) class II currently or within the past  months,
Patients may not have New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < %; patients with a corrected QT (QTc) >  ms, a family history of long QT syndrome, and those on medications known to cause Torsades de Pointes will be excluded from the study
